Urokinase Plasminogen Activator Induces Pro-Fibrotic/M2 Phenotype in Murine Cardiac Macrophages

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Meznarich, Jessica ^a   Malchodi, Laura ^a   Helterline, Deri ^a   Ramsey, Stephen A ^b   Bertko, Kate ^a   Plummer, Tabitha ^a   Plawman, Abigail ^a   Gold, Elizabeth ^b   Stempien Otero, April ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; COLLAGEN; CXCL1 CHEMOKINE; CXCL9 CHEMOKINE; FIBROBLAST GROWTH FACTOR; FIZZ1 PROTEIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; SECRETORY PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; YM1 PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HEART MUSCLE FIBROSIS; M1 GENE; M2 GENE; MACROPHAGE; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PHENOTYPE; TRANSGENE; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

ANIMALS; CELL MOVEMENT; CELL POLARITY; COLLAGEN; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, TRANSGENIC; MYOCARDIUM; PHENOTYPE; TRANSCRIPTION, GENETIC; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84874924453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057837     Document Type: Article

References (52)

1. Devaux B, Scholz D, Hirche A, Klövekorn WP, Schaper J, et al. (1997) Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 18: 470-479.
2. Elsasser A, Decker E, Kostin S, Hein S, Skwara W, et al. (2000) A self-perpetuating vicious cycle of tissue damage in human hibernating myocardium. Mol Cell Biochem 213: 17-28.
3. Berk BC, Fujiwara K, Lehoux S, (2007) ECM remodeling in hypertensive heart disease. J Clin Invest 117: 568-575.
4. Weber K, Brilla C, Janicki J, (1993) Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 27: 341-348.
5. Moreo A, Ambrosio G, De Chiara B, Pu M, Tran T, et al. (2009) Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo. Circ Cardiovasc Imaging 2: 437-443.
6. Pogwizd S, McKenzie J, Cain M, (1998) Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation 98: 2404-2414.
7. Massare J, Berry JM, Luo X, Rob F, Johnstone JL, et al. (2010) Diminished cardiac fibrosis in heart failure is associated with altered ventricular arrhythmia phenotype. J Cardiovasc Electrophysiol 21: 1031-1037.
8. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, et al. (2004) Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 90: 400-405.
9. Laflamme MA, Zbinden S, Epstein SE, Murry CE, (2007) Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu Rev Pathol 2: 307-339.
10. Sun Y, Zhang J, Zhang JQ, Weber KT, (2001) Renin expression at sites of repair in the infarcted rat heart. J Mol Cell Cardiol 33: 995-1003.
11. Mosser DM, Edwards JP, (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
12. Gordon S, Taylor PR, (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964.
13. Torre-Amione G, Kapadia S, Lee J, Durand J, Bies R, et al. (1996) Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93: 704-711.
14. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, et al. (1996) Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28: 964-971.
15. Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, et al. (2008) Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 173: 57-67.
16. Fuchs M, Hilfiker A, Kaminski K, Hilfiker-Kleiner D, Guener Z, et al. (2003) Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. Faseb J 17: 2118-2120.
17. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, et al. (2000) Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A 97: 12746-12751.
18. Mann D, McMurray J, Packer M, Swedberg K, Borer J, et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109: 1594-1602.
19. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, et al. (2009) Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation 119: 1386-1397.
20. Nakajima H, Nakajima H, Salcher O, Dittie A, Dembowsky K, et al. (2000) Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta1 transgene in the heart. Circ Res 86: 571-579.
21. Wunsch M, Sharma H, Market T, (1991) In situ localization of transforming growth factor beta 1 in porcine heart; enhanced expression after chronic coronary artery constriction. J Mol Cell Cardiol 23: 1051-1062.
22. Li K, Xu W, Guo Q, Jiang Z, Wang P, et al. (2009) Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ Res 105: 353-364.
23. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA, (2004) Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 95: 637-644.
24. Stempien-Otero A, Plawman A, Meznarich J, Dyamenahalli T, Otsuka G, et al. (2006) Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. J Biol Chem 281: 15345-15351.
25. Knoepfler PS, Bloor CM, Carroll SM, (1995) Urokinase plasminogen activator activity is increased in the myocardium during coronary artery occlusion. J Mol Cell Cardiol 27: 1317-1324.
26. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, et al. (1999) Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5: 1135-1142.
27. Heymans S, Lupu F, Terclavers S, Vanwetswinkel B, Herbert JM, et al. (2005) Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166: 15-25.
28. Heymans S, Pauschinger M, De Palma A, Kallwellis-Opara A, Rutschow S, et al. (2006) Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 114: 565-573.
29. Cozen AE, Moriwaki H, Kremen M, DeYoung MB, Dichek HL, et al. (2004) Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation 109: 2129-2135.
30. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA, (2004) Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 95: 637-644.
31. Sarkar S, Vellaichamy E, Young D, Sen S, (2004) Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes. Am J Physiol Heart Circ Physiol 287: H107-117.
32. Jones SA, (2005) Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 175: 3463-3468.
33. Minami E, Castellani C, Malchodi L, Deem J, Bertko K, et al. (2010) The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair Urokinase attenuates ventricular remodeling. J Mol Cell Cardiol.
34. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, et al. (1999) Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 163: 3771-3777.
35. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, et al. (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107: 2112-2122.
36. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA, (1999) An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 104: 777-785.
37. Tyagi S, Kumar S, Haas S, Reddy H, Voelker D, et al. (1996) Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol 28: 1415-1428.
38. Griffin MO, Jinno M, Miles LA, Villarreal FJ, (2005) Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition. Mol Cell Biochem 270: 1-11.
39. Banerjee I, Fuseler JW, Intwala AR, Baudino TA, (2009) IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. Am J Physiol Heart Circ Physiol 296: H1694-1704.
40. Gordon S, (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
41. Gyetko MR, Sud S, Chen GH, Fuller JA, Chensue SW, et al. (2002) Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection. J Immunol 168: 801-809.
42. De Taeye BM, Novitskaya T, Gleaves L, Covington JW, Vaughan DE, (2006) Bone marrow plasminogen activator inhibitor-1 influences the development of obesity. J Biol Chem 281: 32796-32805.
43. Allavena P, Mantovani A, (2012) Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 167: 195-205.
44. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N, (1999) Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71: 130-135.
45. Cieslik KA, Taffet GE, Carlson S, Hermosillo J, Trial J, et al. (2011) Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. J Mol Cell Cardiol 50: 248-256.
46. Dupasquier M, Stoitzner P, Wan H, Cerqueira D, van Oudenaren A, et al. (2006) The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of IL-4/IL-13 signaling. J Leukoc Biol 80: 838-849.
47. Lieber A, Vrancken Peeters MJ, Meuse L, Fausto N, Perkins J, et al. (1995) Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo. Proc Natl Acad Sci U S A 92: 6210-6214.
48. Hart DA, Whidden P, Green F, Henkin J, Woods DE, (1994) Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Clin Invest Med 17: 69-76.
49. Yamaguchi I, Lopez-Guisa JM, Cai X, Collins SJ, Okamura DM, et al. (2007) Endogenous urokinase lacks antifibrotic activity during progressive renal injury. Am J Physiol Renal Physiol 293: F12-19.
50. Wynn TA, (2004) Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 4: 583-594.
51. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G, (1993) Transforming growth factor beta1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122: 103-111.
52. Schaffer MR, Efron PA, Thornton FJ, Klingel K, Gross SS, et al. (1997) Nitric oxide, an autocrine regulator of wound fibroblast synthetic function. J Immunol 158: 2375-2381.